FDA inspection
Cephazone Pharma, LLC: FDA inspection ending Sep 19, 2005
FDA inspection 396542 · Voluntary Action Indicated (VAI) · Pomona, CA
Key facts
| Inspection ID | 396542 |
|---|---|
| Firm | Cephazone Pharma, LLC |
| FEI number | 3003701857 |
| Address | 250 E Bonita Ave |
| City | Pomona |
| State | CA |
| ZIP | 91767-1924 |
| Fiscal year | 2005 |
| Inspection end date | Sep 19, 2005 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data